Litigation Details for AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2014)

AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2014)

Docket		Date Filed	2014-04-21
Court	District Court, D. New Jersey	Date Terminated	2014-10-02
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	ROXANE LABORATORIES, INC.
Patents	8,293,728; 8,318,715; 8,357,677; 8,367,652; 8,377,920; 8,399,446; 8,415,335; 8,426,399; 8,431,560; 8,440,650; 8,501,225; 8,518,929; 8,524,698; 8,546,372; 8,551,521; 8,617,594
Attorneys	THEODORA T. MCCORMICK
Link to Docket	External link to docket

Details for AMARIN PHARMA, INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-21				External link to document

Amarin Pharma v. Roxane Laboratories: Vascepa Patent Litigation Summary and Analysis

Last updated: August 5, 2026

Amarin Pharma’s patent case against Roxane Laboratories, Inc., Case No. 3:14-cv-02551 in the U.S. District Court for the District of New Jersey, was an ANDA Paragraph IV action involving generic icosapent ethyl, marketed by Amarin as Vascepa. The case was resolved by settlement rather than trial. The settlement permitted a future generic launch before the full expiration of Amarin’s early Vascepa patent estate, with the reported launch date set for August 22, 2029, subject to contractual early-entry provisions.[1][2]

The case did not produce a final judicial ruling on validity, infringement, or enforceability. Its commercial significance was the preservation of Vascepa exclusivity through most of the patent term while allowing Roxane, later associated with Hikma’s U.S. business, a defined future entry right.

What was Amarin Pharma v. Roxane Laboratories?

Amarin Pharma, Inc. sued Roxane Laboratories, Inc. after Roxane filed an abbreviated new drug application seeking approval to market generic icosapent ethyl capsules before expiration of Amarin’s Vascepa patents.

Item	Detail
Court	U.S. District Court for the District of New Jersey
Case number	3:14-cv-02551
Plaintiff	Amarin Pharma, Inc.
Defendant	Roxane Laboratories, Inc.
Product	Vascepa, icosapent ethyl capsules
Regulatory pathway	ANDA with Paragraph IV certifications
Filing period	2014
Disposition	Settlement and dismissal
Trial or merits judgment	None reported
Reported generic launch date	August 22, 2029, subject to settlement terms
Product category	Small-molecule prescription drug

Vascepa contains icosapent ethyl, an ethyl ester of eicosapentaenoic acid, or EPA. FDA approved Vascepa under NDA 202057 for severe hypertriglyceridemia in July 2012. FDA later approved an expanded indication for reducing cardiovascular risk in certain patients with elevated triglycerides and established cardiovascular disease or diabetes with additional risk factors.[3]

Which patents did Amarin assert against Roxane?

The Roxane litigation involved Amarin’s early Vascepa patent estate, including patents directed to highly purified EPA compositions, pharmaceutical formulations, and methods of treating patients with elevated triglycerides.

Publicly identified patents associated with the Vascepa patent litigation include the following:

Patent	General subject matter	Relevance to Vascepa
U.S. Patent No. 8,293,728	EPA compositions and pharmaceutical use	Core composition and product protection
U.S. Patent No. 8,357,677	Methods involving highly purified EPA	Method-of-use protection
U.S. Patent No. 8,501,728	EPA-containing pharmaceutical compositions	Formulation and composition protection
U.S. Patent No. 8,598,227	Methods for treating triglyceride-related conditions	Method-of-use protection

The precise claims asserted against Roxane must be read together with the complaint, amended pleadings, claim-construction filings, and the parties’ settlement-related dismissal papers. Patent listings and litigation positions can differ because a patent may be listed in the Orange Book but not asserted in every case.

The early patents generally had expiration dates falling around 2030, subject to patent-term adjustment, terminal disclaimers, and the specific patent-family record. The settlement’s August 2029 launch date therefore provided Roxane with an entry date several months before the expected expiration of the principal early patent estate.

Why did Roxane face a Paragraph IV lawsuit?

An ANDA applicant may certify under Paragraph IV that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. The certification creates a statutory basis for the brand company to sue within 45 days of receiving the notice letter. A timely suit can trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions.[4]

Roxane’s ANDA apparently challenged Amarin’s listed Vascepa patents through Paragraph IV certifications. Amarin’s complaint initiated the patent dispute and sought relief that would have prevented FDA approval or commercial marketing of Roxane’s generic product until resolution of the patent claims.

A Paragraph IV case does not establish that the generic product infringes. The brand must prove infringement, and the generic applicant may challenge validity and enforceability. Because Amarin and Roxane settled, the court did not issue a final merits determination.

What was the outcome of the Roxane Vascepa litigation?

The case ended through a settlement agreement and dismissal. The reported commercial terms allowed Roxane to launch a generic version of Vascepa on August 22, 2029, or earlier under specified circumstances.[1][2]

The case therefore produced three principal outcomes:

1. Amarin avoided the risk of an adverse invalidity or noninfringement judgment.
2. Roxane obtained a defined path to commercial entry.
3. The dispute did not establish binding precedent on the validity or infringement of the asserted Vascepa patents.

The settlement date and exact contractual provisions are material. A launch date may be accelerated by events such as a final invalidity ruling in separate litigation, failure of a listed patent, an authorized generic arrangement, or other provisions negotiated by the parties. The settlement itself should control over generalized statements that Roxane was barred until patent expiration.

Did the court decide whether Amarin’s patents were valid?

No. The Roxane case did not result in a final trial judgment resolving patent validity, infringement, written description, enablement, obviousness, anticipation, or inequitable conduct.

That distinction matters for portfolio analysis. A settlement is a commercial resolution, not a judicial confirmation that the patent claims were valid and infringed. It also is not evidence that Roxane’s invalidity or noninfringement positions would have prevailed.

The case should be distinguished from later Vascepa litigation involving other ANDA applicants. Those proceedings generated separate decisions and may have addressed different patents, proposed labels, claim constructions, or factual records. A result against another generic manufacturer cannot automatically be imported into the Roxane docket.

What was the Orange Book status of Vascepa?

Vascepa was listed in the FDA Orange Book with patents covering the approved product and its methods of use. Orange Book listing is central to Hatch-Waxman litigation because it identifies patents that an ANDA applicant must address through Paragraph I, II, III, or IV certifications.

The early Vascepa listings included patents associated with:

• The icosapent ethyl product and its purity profile.
• Pharmaceutical compositions containing highly purified EPA.
• Treatment of severe hypertriglyceridemia.
• Later cardiovascular-risk-reduction methods.
• Formulation and dosing characteristics.

Orange Book status changes over time. A patent may be delisted, expire, or remain listed while litigation concerns only selected claims. The litigation record for Case No. 3:14-cv-02551 should therefore be reviewed against the Orange Book edition and patent-listing status applicable when Roxane filed its ANDA and notice letter.[5]

What formulation patents protected Vascepa?

Vascepa’s patent protection was not limited to the chemical identity of icosapent ethyl. The patent estate also addressed pharmaceutical composition characteristics, including the use of highly purified EPA and the presentation of the active ingredient in oral capsules.

Formulation protection is commercially important because a generic applicant may avoid some claims by changing excipients, capsule composition, manufacturing parameters, or labeling. A patent claim directed to the active ingredient itself is harder to design around than a claim limited to a particular formulation or dosage regimen.

For Vascepa, the relevant technical barriers included:

• High EPA purity.
• Reduced levels of other fatty acids and impurities.
• Oral soft-gel capsule delivery.
• Dosage regimens for triglyceride reduction.
• Use in patients receiving background statin therapy.
• Treatment populations defined by triglyceride levels and cardiovascular risk.

The scope of protection depended on the wording of the asserted claims, not on the commercial description of Vascepa alone.

What method-of-use patents affected generic entry?

Method-of-use patents can delay generic entry when the ANDA label includes a patented indication or instructions that encourage infringement. The legal analysis depends on the proposed label, the scope of the patent claims, and whether the generic applicant can obtain approval with a valid skinny label excluding the patented use.

The Vascepa estate included method claims relating to triglyceride reduction and, later, cardiovascular risk reduction. Those indications created distinct litigation issues:

Issue	Commercial effect
Severe hypertriglyceridemia indication	Earlier approved use and initial patent dispute
Cardiovascular-risk-reduction indication	Later, commercially larger indication
Skinny-label possibility	Could reduce induced-infringement exposure
Label overlap	Could support a claim that the generic encourages patented use
Physician prescribing	Can complicate the practical separation of patented and unpatented uses

A settlement eliminates the need for the court to decide whether Roxane’s proposed label would have induced infringement of Amarin’s method patents.

When does Vascepa lose exclusivity?

Vascepa’s exclusivity has several components, and they should not be treated as interchangeable.

Exclusivity type	Status
FDA new chemical entity exclusivity	Expired before the Roxane litigation
Regulatory exclusivity	Separate from patent protection
Orange Book patent protection	Extended into approximately 2030 for key early patents
Reported Roxane settlement entry	August 22, 2029, subject to early-entry provisions
Biosimilar exclusivity	Not applicable
Generic competition	Controlled by ANDA approval and patent settlements

FDA approval of Vascepa in 2012 granted five years of new chemical entity exclusivity, but that period did not determine the full commercial life of the product. Patent protection and later indication-specific patents became more important to generic-entry timing.

The practical loss of exclusivity may occur before patent expiration if an authorized generic, settlement entrant, or at-risk generic reaches the market. Conversely, patent expiration does not guarantee immediate competition if FDA approval, manufacturing readiness, or supply arrangements delay launch.

Was there a biosimilar risk for Vascepa?

No. Vascepa is a small-molecule drug, not a biologic. Generic competition proceeds through the ANDA pathway, not the Biologics Price Competition and Innovation Act biosimilar pathway.

The relevant competitive risks were:

• Paragraph IV ANDA challenges.
• Paragraph III certifications with delayed approval.
• Skinny-label approval.
• Authorized generic competition.
• At-risk launches after patent litigation.
• Formulation or manufacturing design-arounds.

Biosimilar concepts such as reference-product exclusivity, interchangeability, and biosimilar exclusivity do not apply to icosapent ethyl.

Which companies challenged Amarin’s Vascepa patents?

Roxane was one of several generic or potential generic challengers associated with Vascepa patent disputes. Other cases involved manufacturers and marketing companies that filed ANDAs or pursued generic icosapent ethyl programs. The parties, asserted patents, and outcomes varied by docket.

The competitive landscape included:

• Roxane Laboratories, Inc.
• Hikma Pharmaceuticals and affiliated U.S. entities
• Teva Pharmaceuticals
• Dr. Reddy’s Laboratories
• Other ANDA applicants and generic suppliers

Roxane’s case should not be conflated with later cases against Hikma, Teva, or other applicants. Corporate ownership changes also matter. Roxane was later connected to Hikma’s U.S. operations, but a later corporate relationship does not by itself alter the procedural history of Case No. 3:14-cv-02551.

What was the commercial significance of the settlement?

The settlement protected Amarin’s ability to monetize Vascepa during the period when the product’s cardiovascular indication was becoming commercially important. In exchange, Roxane received a predictable entry date and avoided the cost and uncertainty of trial.

The principal commercial variables were:

• Timing of generic entry.
• The size of the addressable cardiovascular-risk-reduction market.
• Whether other generic applicants obtained earlier entry.
• Whether an authorized generic was launched.
• Reimbursement pressure from payers.
• Manufacturing capacity for icosapent ethyl.
• The effect of later patents on the expanded indication.

Amarin’s revenue exposure was concentrated in Vascepa because the product was its principal commercial asset. Generic entry could affect net sales, pricing, payer coverage, prescription volume, and inventory management. A settlement date in 2029 preserved substantial nominal patent runway but did not eliminate earlier-entry risk from other applicants or litigation outcomes involving later patents.

How strong was Amarin’s patent position after the Roxane settlement?

The settlement indicated that both parties assigned value to litigation risk and entry timing. It did not establish a quantified probability of patent validity or infringement.

A practical strength assessment is:

Factor	Assessment
Composition protection	Stronger where claims covered highly purified EPA rather than narrow excipient combinations
Method-of-use protection	Depended heavily on label scope and induced-infringement evidence
Formulation protection	Potentially more vulnerable to design-around strategies
Patent-family depth	Improved as later indication and formulation patents were added
Litigation precedent from Roxane case	Limited because the case settled
Generic entry certainty	Moderate to high for the reported 2029 date, subject to contractual exceptions
Biosimilar barrier	Not relevant
Manufacturing barrier	Depended on EPA purification, capsule production, quality controls, and FDA approval

The strongest commercial protection came from the combination of patent claims, FDA-listed indications, settlement restrictions, and manufacturing know-how. No single patent should be viewed as the entire Vascepa barrier.

What manufacturing and intellectual-property barriers affected generic launch?

A generic icosapent ethyl applicant needed more than an approved legal theory. It also needed a compliant commercial supply chain.

Relevant barriers included:

• Sourcing marine-derived EPA or suitable precursor material.
• Achieving the required purity specification.
• Controlling oxidation and degradation.
• Producing stable soft-gel capsules.
• Demonstrating pharmaceutical equivalence.
• Meeting FDA chemistry, manufacturing, and controls requirements.
• Scaling production at commercial cost.
• Complying with any non-patent regulatory exclusivity or labeling restrictions.

These operational barriers could delay launch even after patent settlement or expiration. They also could affect the economic attractiveness of an early-entry agreement.

Was Roxane’s case dismissed with prejudice?

The public procedural outcome was settlement and dismissal. Settlement dismissals in Hatch-Waxman cases commonly terminate the litigation without a merits judgment. The precise effect, including whether dismissal was with prejudice and whether the court retained jurisdiction to enforce the agreement, depends on the final dismissal order and settlement-related filings.

The central legal point is that the docket closed without a trial judgment determining that Roxane infringed or that Amarin’s patents were valid.

Key Takeaways

• Amarin sued Roxane in 2014 over a Paragraph IV ANDA for generic Vascepa.
• The case was filed in the District of New Jersey as Case No. 3:14-cv-02551.
• The dispute involved Amarin’s early icosapent ethyl composition, formulation, and method-of-use patents.
• The parties settled instead of proceeding to a final merits decision.
• Roxane reportedly received a right to launch on August 22, 2029, subject to settlement-based early-entry provisions.
• The case created no binding ruling on patent validity, infringement, or enforceability.
• Vascepa is a small molecule, so biosimilar analysis does not apply.
• Generic risk depends on Orange Book patents, later indication patents, other ANDA applicants, settlement terms, manufacturing readiness, and FDA approval status.
• The settlement protected Amarin from immediate Roxane competition but did not eliminate the possibility of earlier entry by other generic manufacturers.

FAQs About Amarin Pharma v. Roxane Laboratories

What drug was involved in the Amarin v. Roxane case?

The case involved Vascepa, a prescription product containing icosapent ethyl. The proposed generic product was intended to contain the same active ingredient in capsule form.

Did Roxane launch generic Vascepa after the settlement?

The settlement reportedly provided a future launch right beginning August 22, 2029, subject to its contractual terms. The litigation docket itself did not establish that Roxane launched a generic product.

Did Amarin win the Roxane patent case?

No merits winner was established. Amarin and Roxane settled, so the court did not decide whether the asserted patents were valid or infringed.

Can an icosapent ethyl generic use a skinny label?

A skinny label may be available if the generic applicant excludes patented indications and complies with FDA labeling requirements. Whether that strategy avoids induced infringement depends on the specific label and patent claims.

Are Vascepa patents listed in the FDA Orange Book?

Yes. FDA Orange Book records identified patents associated with Vascepa, including patents directed to icosapent ethyl compositions and methods of use. The applicable listing must be checked by Orange Book edition and product indication.

References

1. Amarin Pharma, Inc. v. Roxane Laboratories, Inc., No. 3:14-cv-02551, U.S. District Court for the District of New Jersey, docket filings and settlement dismissal materials.

2. Amarin Corporation plc. (2016). Annual report and securities filings describing Vascepa patent litigation and the Roxane settlement. U.S. Securities and Exchange Commission.

3. U.S. Food and Drug Administration. (2012). Vascepa approval history and prescribing information for icosapent ethyl. Drugs@FDA.

4. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book, Vascepa patent listings. FDA.